Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases
BACKGROUND A number of putative stem cell markers have been associated with aggressiveness of prostate cancer, including alpha 2 and alpha 6 integrin and c‐met. The study aimed to test the hypothesis that the development of bone metastasis correlates with the proportion of prostate cancer stem cell‐...
Gespeichert in:
| Veröffentlicht in: | The Prostate 2012-05, Vol.72 (7), p.713-720 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 720 |
|---|---|
| container_issue | 7 |
| container_start_page | 713 |
| container_title | The Prostate |
| container_volume | 72 |
| creator | Colombel, Marc Eaton, Colby L. Hamdy, Freddy Ricci, Estelle van der Pluijm, Gabri Cecchini, Marco Mege-Lechevallier, Florence Clezardin, Philippe Thalmann, George |
| description | BACKGROUND
A number of putative stem cell markers have been associated with aggressiveness of prostate cancer, including alpha 2 and alpha 6 integrin and c‐met. The study aimed to test the hypothesis that the development of bone metastasis correlates with the proportion of prostate cancer stem cell‐like cells present in the primary tumor.
METHODS
Prostate tissue samples were obtained from patients with high‐risk prostatic adenocarcinoma. Prostate cancer tumor tissue samples underwent immunohistochemical staining for alpha 2 and alpha 6 integrin and c‐met; positive and negative controls were included. Samples were scored as positive if >5% of cells within the sample stained positively. Survival and bone metastasis‐free survival curves on the patient cohort were estimated by the actuarial method of Kaplan–Meier.
RESULTS
A total of 62 patients were included in the study. Bone metastases progression rate was 46% at 105 months with a median time of 46 months (95% CI: 1–62.5 months); prostate cancer‐specific survival was 33% at 122 months with a median survival time of 69.4 months (95% CI: 63.5–109.4 months). Survival curves show that c‐met‐, alpha 2, and alpha 6 integrin‐positive tumors were positively associated with the occurrence of bone metastasis‐free survival. There was a higher level of significance when at least c‐met and either alpha 2 or alpha 6 integrin was positive.
CONCLUSION
It can be concluded that percentage of stem cell‐like prostate cancer cells has a prognostic impact especially on the risk of metastatic bone progression. Prostate 72:713–720, 2012. © 2011 Wiley Periodicals, Inc. |
| doi_str_mv | 10.1002/pros.21473 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1009526236</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1009526236</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3973-9d567a7408ffa6354bf8a167e3782d9867634f9a6c58d90edcb16e4007dca9c73</originalsourceid><addsrcrecordid>eNp9kctuFDEQRS1ERCaBDR-AvEFCSB386PZjCQGSSFGCMqBI2VgedzUY-jG4evL4Ab477sxkYMXKKuvUrbq3CHnJ2QFnTLxbpgEPBC-1fEJmnFldMFZWT8mMCc2Kkku9S_YQfzKWcSaekV3BjRGC8xn5c9KHBB6hpnC7TIAYh54ODV2uRj_Ga6DB9wESxRE6GqBtaefTL0hIY0-XKebqjk4bZHwLR6QecQgx_9X0Jo4_JuT7P_KLoQfawehzHwI-JzuNbxFebN598u3zp6-Hx8Xp-dHJ4fvTIkirZWHrSmmvS2aaxitZlYvGeK40SG1EbY3SSpaN9SpUprYM6rDgCkrGdB28DVrukzdr3bzO7xXg6LqIkyvfw7BClwOylVBCqoy-XaMhm8MEjdu4zdDECTe5dg-5Z_jVRne16KDeoo9BZ-D1BvAYfNukHFTEv1yljVVmmsrX3E1s4e4_I92Xi_P54_Bi3RPzkW63PflMTmmpK3d5duTYFf_wcX42dxfyHrlHrL4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1009526236</pqid></control><display><type>article</type><title>Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Colombel, Marc ; Eaton, Colby L. ; Hamdy, Freddy ; Ricci, Estelle ; van der Pluijm, Gabri ; Cecchini, Marco ; Mege-Lechevallier, Florence ; Clezardin, Philippe ; Thalmann, George</creator><creatorcontrib>Colombel, Marc ; Eaton, Colby L. ; Hamdy, Freddy ; Ricci, Estelle ; van der Pluijm, Gabri ; Cecchini, Marco ; Mege-Lechevallier, Florence ; Clezardin, Philippe ; Thalmann, George</creatorcontrib><description>BACKGROUND
A number of putative stem cell markers have been associated with aggressiveness of prostate cancer, including alpha 2 and alpha 6 integrin and c‐met. The study aimed to test the hypothesis that the development of bone metastasis correlates with the proportion of prostate cancer stem cell‐like cells present in the primary tumor.
METHODS
Prostate tissue samples were obtained from patients with high‐risk prostatic adenocarcinoma. Prostate cancer tumor tissue samples underwent immunohistochemical staining for alpha 2 and alpha 6 integrin and c‐met; positive and negative controls were included. Samples were scored as positive if >5% of cells within the sample stained positively. Survival and bone metastasis‐free survival curves on the patient cohort were estimated by the actuarial method of Kaplan–Meier.
RESULTS
A total of 62 patients were included in the study. Bone metastases progression rate was 46% at 105 months with a median time of 46 months (95% CI: 1–62.5 months); prostate cancer‐specific survival was 33% at 122 months with a median survival time of 69.4 months (95% CI: 63.5–109.4 months). Survival curves show that c‐met‐, alpha 2, and alpha 6 integrin‐positive tumors were positively associated with the occurrence of bone metastasis‐free survival. There was a higher level of significance when at least c‐met and either alpha 2 or alpha 6 integrin was positive.
CONCLUSION
It can be concluded that percentage of stem cell‐like prostate cancer cells has a prognostic impact especially on the risk of metastatic bone progression. Prostate 72:713–720, 2012. © 2011 Wiley Periodicals, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.21473</identifier><identifier>PMID: 21882211</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adenocarcinoma - metabolism ; Adenocarcinoma - secondary ; Adenocarcinoma - surgery ; Aged ; Aged, 80 and over ; alpha 2 integrin ; alpha 6 integrin ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Biomarkers, Tumor - metabolism ; bone metastasis ; Bone Neoplasms - metabolism ; Bone Neoplasms - secondary ; c-met ; Cohort Studies ; Disease Progression ; Disease-Free Survival ; Gynecology. Andrology. Obstetrics ; Humans ; immunohistochemistry ; Integrin alpha2 - analysis ; Integrin alpha6 - analysis ; Male ; Male genital diseases ; Medical sciences ; Middle Aged ; Neoplastic Stem Cells - metabolism ; Nephrology. Urinary tract diseases ; Prognosis ; prostate cancer ; Prostatic Neoplasms - metabolism ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - surgery ; Proto-Oncogene Proteins c-met - analysis ; survival ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>The Prostate, 2012-05, Vol.72 (7), p.713-720</ispartof><rights>Copyright © 2011 Wiley Periodicals, Inc.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3973-9d567a7408ffa6354bf8a167e3782d9867634f9a6c58d90edcb16e4007dca9c73</citedby><cites>FETCH-LOGICAL-c3973-9d567a7408ffa6354bf8a167e3782d9867634f9a6c58d90edcb16e4007dca9c73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.21473$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.21473$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25789686$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21882211$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Colombel, Marc</creatorcontrib><creatorcontrib>Eaton, Colby L.</creatorcontrib><creatorcontrib>Hamdy, Freddy</creatorcontrib><creatorcontrib>Ricci, Estelle</creatorcontrib><creatorcontrib>van der Pluijm, Gabri</creatorcontrib><creatorcontrib>Cecchini, Marco</creatorcontrib><creatorcontrib>Mege-Lechevallier, Florence</creatorcontrib><creatorcontrib>Clezardin, Philippe</creatorcontrib><creatorcontrib>Thalmann, George</creatorcontrib><title>Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>BACKGROUND
A number of putative stem cell markers have been associated with aggressiveness of prostate cancer, including alpha 2 and alpha 6 integrin and c‐met. The study aimed to test the hypothesis that the development of bone metastasis correlates with the proportion of prostate cancer stem cell‐like cells present in the primary tumor.
METHODS
Prostate tissue samples were obtained from patients with high‐risk prostatic adenocarcinoma. Prostate cancer tumor tissue samples underwent immunohistochemical staining for alpha 2 and alpha 6 integrin and c‐met; positive and negative controls were included. Samples were scored as positive if >5% of cells within the sample stained positively. Survival and bone metastasis‐free survival curves on the patient cohort were estimated by the actuarial method of Kaplan–Meier.
RESULTS
A total of 62 patients were included in the study. Bone metastases progression rate was 46% at 105 months with a median time of 46 months (95% CI: 1–62.5 months); prostate cancer‐specific survival was 33% at 122 months with a median survival time of 69.4 months (95% CI: 63.5–109.4 months). Survival curves show that c‐met‐, alpha 2, and alpha 6 integrin‐positive tumors were positively associated with the occurrence of bone metastasis‐free survival. There was a higher level of significance when at least c‐met and either alpha 2 or alpha 6 integrin was positive.
CONCLUSION
It can be concluded that percentage of stem cell‐like prostate cancer cells has a prognostic impact especially on the risk of metastatic bone progression. Prostate 72:713–720, 2012. © 2011 Wiley Periodicals, Inc.</description><subject>Adenocarcinoma - metabolism</subject><subject>Adenocarcinoma - secondary</subject><subject>Adenocarcinoma - surgery</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>alpha 2 integrin</subject><subject>alpha 6 integrin</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>bone metastasis</subject><subject>Bone Neoplasms - metabolism</subject><subject>Bone Neoplasms - secondary</subject><subject>c-met</subject><subject>Cohort Studies</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>immunohistochemistry</subject><subject>Integrin alpha2 - analysis</subject><subject>Integrin alpha6 - analysis</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplastic Stem Cells - metabolism</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prognosis</subject><subject>prostate cancer</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Proto-Oncogene Proteins c-met - analysis</subject><subject>survival</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctuFDEQRS1ERCaBDR-AvEFCSB386PZjCQGSSFGCMqBI2VgedzUY-jG4evL4Ab477sxkYMXKKuvUrbq3CHnJ2QFnTLxbpgEPBC-1fEJmnFldMFZWT8mMCc2Kkku9S_YQfzKWcSaekV3BjRGC8xn5c9KHBB6hpnC7TIAYh54ODV2uRj_Ga6DB9wESxRE6GqBtaefTL0hIY0-XKebqjk4bZHwLR6QecQgx_9X0Jo4_JuT7P_KLoQfawehzHwI-JzuNbxFebN598u3zp6-Hx8Xp-dHJ4fvTIkirZWHrSmmvS2aaxitZlYvGeK40SG1EbY3SSpaN9SpUprYM6rDgCkrGdB28DVrukzdr3bzO7xXg6LqIkyvfw7BClwOylVBCqoy-XaMhm8MEjdu4zdDECTe5dg-5Z_jVRne16KDeoo9BZ-D1BvAYfNukHFTEv1yljVVmmsrX3E1s4e4_I92Xi_P54_Bi3RPzkW63PflMTmmpK3d5duTYFf_wcX42dxfyHrlHrL4</recordid><startdate>20120515</startdate><enddate>20120515</enddate><creator>Colombel, Marc</creator><creator>Eaton, Colby L.</creator><creator>Hamdy, Freddy</creator><creator>Ricci, Estelle</creator><creator>van der Pluijm, Gabri</creator><creator>Cecchini, Marco</creator><creator>Mege-Lechevallier, Florence</creator><creator>Clezardin, Philippe</creator><creator>Thalmann, George</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120515</creationdate><title>Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases</title><author>Colombel, Marc ; Eaton, Colby L. ; Hamdy, Freddy ; Ricci, Estelle ; van der Pluijm, Gabri ; Cecchini, Marco ; Mege-Lechevallier, Florence ; Clezardin, Philippe ; Thalmann, George</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3973-9d567a7408ffa6354bf8a167e3782d9867634f9a6c58d90edcb16e4007dca9c73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adenocarcinoma - metabolism</topic><topic>Adenocarcinoma - secondary</topic><topic>Adenocarcinoma - surgery</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>alpha 2 integrin</topic><topic>alpha 6 integrin</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>bone metastasis</topic><topic>Bone Neoplasms - metabolism</topic><topic>Bone Neoplasms - secondary</topic><topic>c-met</topic><topic>Cohort Studies</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>immunohistochemistry</topic><topic>Integrin alpha2 - analysis</topic><topic>Integrin alpha6 - analysis</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplastic Stem Cells - metabolism</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prognosis</topic><topic>prostate cancer</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Proto-Oncogene Proteins c-met - analysis</topic><topic>survival</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Colombel, Marc</creatorcontrib><creatorcontrib>Eaton, Colby L.</creatorcontrib><creatorcontrib>Hamdy, Freddy</creatorcontrib><creatorcontrib>Ricci, Estelle</creatorcontrib><creatorcontrib>van der Pluijm, Gabri</creatorcontrib><creatorcontrib>Cecchini, Marco</creatorcontrib><creatorcontrib>Mege-Lechevallier, Florence</creatorcontrib><creatorcontrib>Clezardin, Philippe</creatorcontrib><creatorcontrib>Thalmann, George</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Colombel, Marc</au><au>Eaton, Colby L.</au><au>Hamdy, Freddy</au><au>Ricci, Estelle</au><au>van der Pluijm, Gabri</au><au>Cecchini, Marco</au><au>Mege-Lechevallier, Florence</au><au>Clezardin, Philippe</au><au>Thalmann, George</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2012-05-15</date><risdate>2012</risdate><volume>72</volume><issue>7</issue><spage>713</spage><epage>720</epage><pages>713-720</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>BACKGROUND
A number of putative stem cell markers have been associated with aggressiveness of prostate cancer, including alpha 2 and alpha 6 integrin and c‐met. The study aimed to test the hypothesis that the development of bone metastasis correlates with the proportion of prostate cancer stem cell‐like cells present in the primary tumor.
METHODS
Prostate tissue samples were obtained from patients with high‐risk prostatic adenocarcinoma. Prostate cancer tumor tissue samples underwent immunohistochemical staining for alpha 2 and alpha 6 integrin and c‐met; positive and negative controls were included. Samples were scored as positive if >5% of cells within the sample stained positively. Survival and bone metastasis‐free survival curves on the patient cohort were estimated by the actuarial method of Kaplan–Meier.
RESULTS
A total of 62 patients were included in the study. Bone metastases progression rate was 46% at 105 months with a median time of 46 months (95% CI: 1–62.5 months); prostate cancer‐specific survival was 33% at 122 months with a median survival time of 69.4 months (95% CI: 63.5–109.4 months). Survival curves show that c‐met‐, alpha 2, and alpha 6 integrin‐positive tumors were positively associated with the occurrence of bone metastasis‐free survival. There was a higher level of significance when at least c‐met and either alpha 2 or alpha 6 integrin was positive.
CONCLUSION
It can be concluded that percentage of stem cell‐like prostate cancer cells has a prognostic impact especially on the risk of metastatic bone progression. Prostate 72:713–720, 2012. © 2011 Wiley Periodicals, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>21882211</pmid><doi>10.1002/pros.21473</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 2012-05, Vol.72 (7), p.713-720 |
| issn | 0270-4137 1097-0045 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1009526236 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adenocarcinoma - metabolism Adenocarcinoma - secondary Adenocarcinoma - surgery Aged Aged, 80 and over alpha 2 integrin alpha 6 integrin Biological and medical sciences Biomarkers, Tumor - analysis Biomarkers, Tumor - metabolism bone metastasis Bone Neoplasms - metabolism Bone Neoplasms - secondary c-met Cohort Studies Disease Progression Disease-Free Survival Gynecology. Andrology. Obstetrics Humans immunohistochemistry Integrin alpha2 - analysis Integrin alpha6 - analysis Male Male genital diseases Medical sciences Middle Aged Neoplastic Stem Cells - metabolism Nephrology. Urinary tract diseases Prognosis prostate cancer Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology Prostatic Neoplasms - surgery Proto-Oncogene Proteins c-met - analysis survival Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T12%3A02%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20expression%20of%20putative%20cancer%20stem%20cell%20markers%20in%20primary%20prostate%20cancer%20is%20associated%20with%20progression%20of%20bone%20metastases&rft.jtitle=The%20Prostate&rft.au=Colombel,%20Marc&rft.date=2012-05-15&rft.volume=72&rft.issue=7&rft.spage=713&rft.epage=720&rft.pages=713-720&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.21473&rft_dat=%3Cproquest_cross%3E1009526236%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1009526236&rft_id=info:pmid/21882211&rfr_iscdi=true |